Samer Al Hadidi

Sourced from institutional research profiles (UAMS TRI or ARA).

Associate Professor , Clinical Director of Amyloidosis Program

UAMS

Also affiliated: Houston Methodist (2021); The University of Texas MD Anderson Cancer Center (2020–2022); Baylor College of Medicine (2018–2022); University of Arkansas Medical Center (2022–2025); Hurley Medical Center (2016–2018); Gene Therapy Laboratory (2021); University of Michigan–Flint (2014–2017); Southwestern Medical Center (2025–2026); Methodist Hospital (2021); Palmetto Hematology Oncology (2023); Winthrop Rockefeller Foundation (2021–2025); Texas Children's Hospital (2021); Arkansas Department of Agriculture (2024); Southwestern Medical Center (2025–2026); Indiana University School of Medicine (2023); Indiana University (2023); The University of Texas Southwestern Medical Center (2025–2026); Michigan State University (2014–2018)

Faculty Researcher

21 h-index 245 pubs 1,812 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Samer Al Hadidi, M.D., M.S., is an Associate Professor specializing in hematology and oncology, with a focus on plasma cell disorders and cellular therapies. His clinical work includes directing the Amyloidosis Program and leading the Fellows’ Plasma Cell Disorders Clinic. Dr. Al Hadidi earned his medical degree from the University of Jordan School of Medicine and completed his internal medicine residency at Hurley Medical Center/Michigan State University. He pursued fellowship training in hematology and oncology at Baylor College of Medicine and obtained a master’s degree in clinical research and statistical analysis from the University of Michigan.

Dr. Al Hadidi’s research investigates treatments for multiple myeloma and related conditions. He has published on the risk of infections associated with bispecific antibodies in multiple myeloma, the participation of Black Americans in cancer clinical trials, and disparities in access to CAR T-cell and bispecific antibody trials for multiple myeloma. His work also characterizes the immune microenvironment in multiple myeloma progression at a single-cell level and examines the changing spectrum of infections with BCMA and GPRC5D targeting bispecific antibody therapy. He has an h-index of 20 and has authored 240 publications, with 1,583 citations.

Metrics

h-index: 21
Publications: 245
Citations: 1,812

Selected Publications

Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

DOI OpenAlex
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)

Blood Cancer Journal 1 citation DOI OpenAlex
Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma (2025)

Blood 9 citations DOI OpenAlex
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2025)

Blood Cancer Journal 14 citations DOI OpenAlex
Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis (2025)

Clinical Hematology International 2 citations DOI OpenAlex
MM-1225: Comparison of Short-Term Outcomes and Safety Profile Between Daratumumab-Based Quadruplet Versus Triplet Induction Regimens for Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma: Meta-Analysis of Randomized Controlled Trials (2025)

DOI OpenAlex
Bispecific antibody therapy in <scp>CNS</scp> myeloma: Early evidence from a multicentre cohort (2025)

British Journal of Haematology 4 citations DOI OpenAlex
The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia (2025)

Blood Advances 4 citations DOI OpenAlex
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging (2025)

Blood Advances 1 citation DOI OpenAlex
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

Cancer Biomarkers 1 citation DOI OpenAlex
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)

JAMA Oncology 6 citations DOI OpenAlex
Current and Future Directions of Immunotherapies in Multiple Myeloma (2025)

American Society of Clinical Oncology Educational Book 1 citation DOI OpenAlex
Bispecific antibody therapy in central nervous system (CNS) multiple myeloma (MM): Multicenter retrospective study. (2025)

Journal of Clinical Oncology 2 citations DOI OpenAlex
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)

Frontiers in Hematology 1 citation DOI OpenAlex
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025)

Blood Cancer Journal 32 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients Caelum Biosciences, Inc via IQVIA, Inc.
276346 S2209, A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance SouthWest Oncology Group
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA Pfizer, Inc.